[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601562":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":58,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":89,"whyStopped":26,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"VA Office of Research and Development","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active rTMS","EXPERIMENTAL","Receive active rTMS",[13],"Device: Repetitive transcranial magnetic stimulation (rTMS)",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham rTMS","SHAM_COMPARATOR","Receive sham rTMS",[19],"Device: Sham rTMS",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Repetitive transcranial magnetic stimulation (rTMS)","rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 30 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Subjects randomized to sham rTMS will undergo the same procedures on the same equipment as subjects assigned to active rTMS, but no active magnetic stimulation will be delivered.",[15],[31],{"name":32,"affiliation":33,"role":34},"Jong H. Yoon, MD","VA Palo Alto Health Care System, Palo Alto, CA","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Jong H Yoon, MD","CONTACT","(650) 493-5000","jhyoon1@stanford.edu",[42],{"facility":33,"status":26,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Palo Alto","California","94304-1207","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-122.14302,37.44188,{"lat":52,"lon":51},[55,57],{"name":37,"role":38,"phone":56,"phoneExt":26,"email":40},"650-493-5000",{"name":32,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":59,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[61],{"name":62,"class":63},"Stanford University","OTHER","100601562","repetitive-transcranial-magnetic-stimulation-treatment-of-stimulant-use-disorder-100601562",false,"NCT07112105","Repetitive Transcranial Magnetic Stimulation Treatment of Stimulant Use Disorder","VA-StARTS","Inclusion Criteria:\n\n* Structured Clinical Interview for DSM Disorders (SCID) confirmed diagnosis of SUD, severe\n* Last use of stimulants \\>2 and \\\u003C8 weeks\n* Stable medication regimen (no change in dose or agents between 2 weeks prior to the start of and throughout the treatment phase of the study)\n* Stable medical health\n\nExclusion Criteria:\n\n* Pregnant or lactating female\n* History of prior adverse reaction to TMS\n* On medications thought to significantly lower seizure threshold, e.g. clozapine, chlorpromazine, clomipramine, and bupropion \\> 400mg\u002Fday\n* Seizure disorder or conditions known to substantially increase risk for seizures\n* Implants or medical devices incompatible with TMS\n* Acute or unstable chronic medical illness that would affect participation or compliance in the study, e.g. unstable angina\n* Unstable psychiatric symptoms that precludes consistent participation in the study, e.g. active current suicidal intent or plan; severe psychosis\n* Other substance use disorder not in remission\n* Chronic or recurring Axis I psychotic disorders\n* For subjects participating in fMRI scans, presence of ferromagnetic material in their body or taking DAergic medications","ALL","18 Years","65 Years",{"count":75,"type":76},106,"ESTIMATED","INTERVENTIONAL",[79],"NA","The purpose of this study is to establish a new treatment (repetitive transcranial stimulation (rTMS)) for Veterans with stimulant use disorder (SUD). Despite the large public health burden imposed by SUD, there is currently no FDA-approved or widely recognized effective somatic treatment. This placebo controlled study will test the effectiveness of rTMS in the treatment of SUD, and explore biomarkers that may guide patient selection for rTMS treatment and predict treatment response.",[82],"Stimulant Use Disorder",[84,85,86,87,88],"Magnetic resonance imaging","Transcranial magnetic stimulation","Intermittent theta burst stimulation","Dopamine","Reward processing","NOT_YET_RECRUITING","2026-03-27",{"date":92,"type":93},"2026-04-02","ACTUAL",{"date":95,"type":76},"2026-05-01",{"date":97,"type":76},"2029-12-31",{"name":5,"class":6},1]